Company
United StatesPublic company, NASDAQ: RDHLREDHILL BIOPHARMA INC. (NASDAQ: RDHL), Raleigh, NC – FDA Inspections
Inspection records and compliance data for REDHILL BIOPHARMA INC. in Raleigh, North Carolina. 1 FDA inspection on record, last inspected August 25, 2022. Publicly traded as NASDAQ: RDHL.
Company Profile
This profile covers REDHILL BIOPHARMA INC. based in Raleigh, North Carolina, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected August 25, 2022.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| August 25, 2022 | NAI | Human Drugs · Bioresearch Monitoring | 1179443 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
REDHILL BIOPHARMA INC.
Stock ticker
RDHL
Exchange
NASDAQ
Share price
$0.42
Market cap
$3.7M
Price as of
November 6, 2026
FEI Number
3016555114
Address
8041 Arco Corporate Dr Ste 200, Raleigh, North Carolina 27617, United States
Country
United States
ID: 98fd3f0e-dbc2-4bbf-bfb9-9efd85c352b5